MRNA ▼ -5.3% - Moderna, Inc.
$MRNA - Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
Moderna received U.S. FDA approval for its updated COVID-19 vaccines for the 2026-2027 season, yet shares fell 5.3% today. The decline suggests investors may be concerned about declining demand for COVID-19 vaccines as the pandemic recedes, or they were pricing in higher expectations for the approval announcement. The regulatory clearance itself represents a positive development for the company's vaccine pipeline, but market sentiment appears focused on longer-term revenue headwinds in this category.
27-AUG-2026 03:57 PM ET
Share this post
More filings for $MRNA
MRNA ▼ -0.5% - Moderna, Inc.Nov 12, 2026MRNA ▼ -1.1% - Moderna, Inc.Nov 11, 2026MRNA ▲ +2.2% - Moderna, Inc.Nov 11, 2026MRNA ▲ +0.8% - Moderna, Inc.Nov 10, 2026MRNA ▲ +1.9% - Moderna, Inc.Nov 9, 2026MRNA ▲ +8.1% - Moderna, Inc.Nov 6, 2026
View full $MRNA filing history →💬 Comments
Loading comments…
Leave a comment
